Literature DB >> 26023666

Epithelial borderline ovarian tumor: Diagnosis and treatment strategy.

Kimio Ushijima1, Kouichiro Kawano1, Naotake Tsuda1, Shin Nishio1, Atsumu Terada1, Hiroyuki Kato1, Kazuto Tasaki1, Ken Matsukuma1.   

Abstract

Epithelial borderline ovarian tumors (BOT) are distinctive from benign tumors and carcinoma. They occur in younger women more often than carcinoma, and there is some difficulty making correct diagnosis of BOT. Two subtypes of BOT, serous and mucinous borderline tumor have different characteristics and very different clinical behavior. Serous borderline tumor (SBT) with micropapillary pattern shows more incidence of extra ovarian disease and often coexists with invasive implant. SBT with micropapillary pattern in advanced stage has showed a worse prognosis than typical SBT. Huge mucinous borderline tumors have histologic heterogeneity, and the accuracy of frozen section diagnosis is relatively low. Extensive sampling is required to reach a correct pathological diagnosis. Mucinous adenoma (intestinal type) also runs the risk of recurrence after cystectomy, or intraoperative rupture of cyst. Laparoscopic procedure for BOT has not increased the risk of recurrence. Fertility preserving procedures are generally accepted, except in advanced stage SBT with invasive implants. Only cystectomy shows a significant risk of recurrence. Re-staging surgery and full staging surgery is not necessary for all BOT. We should not attempt to treat them uniformly, by the single diagnosis of "borderline tumor". It depends on histologic type. Close communication with the pathologist is necessary to gain more detail and ask more pathological samples in order to make the optimal treatment strategy for each individual patients.

Entities:  

Keywords:  Borderline ovarian tumor; Laparoscopy; Mucinous borderline tumor; Recurrence; Serous borderline tumor

Year:  2015        PMID: 26023666      PMCID: PMC4444513          DOI: 10.5468/ogs.2015.58.3.183

Source DB:  PubMed          Journal:  Obstet Gynecol Sci        ISSN: 2287-8572


  13 in total

1.  Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.

Authors:  J D Seidman; R J Kurman
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).

Authors:  Martin Koskas; Catherine Uzan; Sebastien Gouy; Patricia Pautier; Catherine Lhommé; Christine Haie-Meder; Pierre Duvillard; Philippe Morice
Journal:  Ann Surg Oncol       Date:  2010-08-25       Impact factor: 5.344

3.  Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?

Authors:  Andres G Chiesa; Michael T Deavers; Emanuela Veras; Elvio G Silva; David Gershenson; Anais Malpica
Journal:  Int J Gynecol Pathol       Date:  2010-03       Impact factor: 2.762

4.  Does intraoperative spillage of benign ovarian mucinous cystadenoma increase its recurrence rate?

Authors:  Ido Ben-Ami; Noam Smorgick; Josef Tovbin; Noga Fuchs; Reuvit Halperin; Moty Pansky
Journal:  Am J Obstet Gynecol       Date:  2009-12-21       Impact factor: 8.661

Review 5.  Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.

Authors:  Heidi W Shappell; Maureen A Riopel; Ann E Smith Sehdev; Brigitte M Ronnett; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2002-12       Impact factor: 6.394

Review 6.  Mucinous tumors of the ovary: a review.

Authors:  William R Hart
Journal:  Int J Gynecol Pathol       Date:  2005-01       Impact factor: 2.762

7.  Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

Authors:  Debra A Bell; Teri A Longacre; Jaime Prat; Elise C Kohn; Robert A Soslow; Lora H Ellenson; Anais Malpica; Mark H Stoler; Robert J Kurman
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

8.  Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors.

Authors:  Jean-Luc Brun; Annie Cortez; Roman Rouzier; Patrice Callard; Marc Bazot; Serge Uzan; Emile Daraï
Journal:  Am J Obstet Gynecol       Date:  2008-05-19       Impact factor: 8.661

9.  Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.

Authors:  Raffaèle Fauvet; Joëlle Boccara; Charlotte Dufournet; Emmanuel David-Montefiore; Christophe Poncelet; Emile Daraï
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

10.  A comparative analysis of lymphatic vessel density in ovarian serous tumors of low malignant potential (borderline tumors) with and without lymph node involvement.

Authors:  Oluwole Fadare; Michael P Orejudos; Reena Jain; M Rajan Mariappan; Jonathan L Hecht; Idris L Renshaw; Denise Hileeto; Sa A Wang; Mohiedean Ghofrani; Sharon X Liang
Journal:  Int J Gynecol Pathol       Date:  2008-10       Impact factor: 2.762

View more
  5 in total

1.  Borderline tumors of the ovary: A clinicopathological study.

Authors:  Samia Yasmeen; Abdul Hannan; Fareeha Sheikh; Amir Ali Syed; Neelam Siddiqui
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

2.  Pelvic Inflammatory Disease: Possible Catches and Correct Management in Young Women.

Authors:  Chiara Di Tucci; Daniele Di Mascio; Michele Carlo Schiavi; Giorgia Perniola; Ludovico Muzii; Pierluigi Benedetti Panici
Journal:  Case Rep Obstet Gynecol       Date:  2018-07-11

3.  Clinical Analysis of 17 Cases of Borderline Ovarian Tumors During Pregnancy.

Authors:  Mingdan Wang; Yue Li; Tongtong Xu; Chen Shi; Lili Jiang; Kuiran Liu
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 4.  The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.

Authors:  Yu Sun; Juan Xu; Xuemei Jia
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

5.  High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival.

Authors:  Laurence Faucher-Giguère; Audrey Roy; Gabrielle Deschamps-Francoeur; Sonia Couture; Ryan M Nottingham; Alan M Lambowitz; Michelle S Scott; Sherif Abou Elela
Journal:  NAR Cancer       Date:  2022-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.